Haemonetics Corporation $HAE Stock Holdings Lowered by Skylands Capital LLC

Skylands Capital LLC lowered its stake in shares of Haemonetics Corporation (NYSE:HAE) by 54.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 21,700 shares of the medical instruments supplier’s stock after selling 25,925 shares during the quarter. Skylands Capital LLC’s holdings in Haemonetics were worth $2,285,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after acquiring an additional 233,119 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its stake in shares of Haemonetics by 17.3% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock valued at $47,400,000 after acquiring an additional 124,020 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Haemonetics by 1,191.9% in the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after acquiring an additional 418,470 shares during the period. Bank of America Corp DE bought a new stake in shares of Haemonetics in the 2nd quarter worth about $33,326,000. Finally, London Co. of Virginia lifted its holdings in shares of Haemonetics by 33.9% in the 1st quarter. London Co. of Virginia now owns 352,807 shares of the medical instruments supplier’s stock worth $19,884,000 after acquiring an additional 89,242 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Barrington Research lifted their price target on shares of Haemonetics from $118.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, October 9th. Weiss Ratings raised shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. raised their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Raymond James Financial boosted their target price on Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $116.93 on Thursday. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. The stock’s fifty day moving average is $107.30 and its two-hundred day moving average is $83.13. Haemonetics Corporation has a 52 week low of $48.98 and a 52 week high of $123.77. The company has a market capitalization of $5.32 billion, a PE ratio of 57.32, a price-to-earnings-growth ratio of 2.36 and a beta of 0.61.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The business had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $1.10 earnings per share. As a group, analysts expect that Haemonetics Corporation will post 5.29 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.